Prevalence and awareness of cardiovascular risk factors in patients with schizophrenia: A cross-sectional study in a low cardiovascular disease risk geographical area

European Psychiatry

Volumn 24, Issue 7, 2009, Pages 431-441

  Bernardo, M ^a   Canas F ^b   Banegas, J R ^c   Casademont, J ^d   Riesgo, Y ^e   Varela, C ^e  

^a HOSPITAL CLÍNIC   (Spain)

^b Hospital Dr Rodríguez Lafora   (Spain)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^d HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^e BRISTOL MYERS SQUIBB   (United States)

Author keywords

Comorbidity; Disease management; Physical health; Risk factors; Schizophrenia

Indexed keywords

AMISULPRIDE; ANXIOLYTIC AGENT; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; HYPNOTIC SEDATIVE AGENT; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE; ZUCLOPENTHIXOL;

ADULT; ARTICLE; CARDIOVASCULAR RISK; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DYSLIPIDEMIA; FATALITY; FEMALE; HIGH RISK POPULATION; HOSPITAL ADMISSION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OBESITY; PREVALENCE; PRIORITY JOURNAL; SCHIZOPHRENIA; SEX DIFFERENCE; SMOKING;

EID: 70350063813     PISSN: 09249338     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eurpsy.2009.07.010     Document Type: Article

References (42)

1. Alvarez-Sala L.A., Suarez C., Mantilla T., Franch J., Ruilope L.M., Banegas J.R., et al. PREVENCAT study: control of cardiovascular risk in primary care. Med Clin (Barc) 124 11 (2005) 406-410
2. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry 2004;65(2):267-72.
3. American Psychiatric Association. DSM-IV-TR. Manual de Diagnostico y Estadístico de los Trastornos Mentales, cuarta edición, texto revisado. Barcelona: Editorial Masson; 2002.
4. Asociación Española de Neuropsiquiatría. Mental Health Observatory: Analysis of Mental Health Resources in Spain. Internet Publication. 2003.
5. Bobes J., Arango C., Aranda P., Carmena R., Garcia-Garcia M., and Rejas J. Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS Study. Schizophr Res 90 1-3 (2007) 162-173
6. Bobes J., Rejas J., Garcia-Garcia M., Rico-Villademoros F., Garcia-Portilla M.P., Fernandez I., et al. Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study. Schizophr Res 62 1-2 (2003) 77-88
7. Bushe C., and Paton C. The potential impact of antipsychotics on lipids in schizophrenia: is there enough evidence to confirm a link?. J Psychopharmacol 19 6 Suppl. (2005) 76-83
8. Cannon C.P., Battler A., Brindis R.G., Cox J.L., Ellis S.G., Every N.R., et al. American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes. A report of the American College of Cardiology Task Force on Clinical Data Standards (Acute Coronary Syndromes Writing Committee). J Am Coll Cardiol 38 7 (2001) 2114-2130
9. Casey D.E., Haupt D.W., Newcomer J.W., Henderson D.C., Sernyak M.J., Davidson M., et al. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J Clin Psychiatry 65 Suppl. 7 (2004) 4-18
10. Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo Jr. J.L., et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289 19 (2003) 2560-2572
11. Citrome L., and Yeomans D. Do guidelines for severe mental illness promote physical health and well-being?. J Psychopharmacol 19 6 Suppl. (2005) 102-109
12. Cohn T., Prud'homme D., Streiner D., Kameh H., and Remington G. Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Can J Psychiatry 49 11 (2004) 753-760
13. Conroy R.M., Pyorala K., Fitzgerald A.P., Sans S., Menotti A., De B.G., et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 24 11 (2003) 987-1003
14. Correll C.U., Frederickson A.M., Kane J.M., and Manu P. Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics. Bipolar Disord 10 7 (2008) 788-797
15. Curkendall S.M., Mo J., Glasser D.B., Rose S.M., and Jones J.K. Cardiovascular disease in patients with schizophrenia in Saskatchewan, Canada. J Clin Psychiatry 65 5 (2004) 715-720
16. Davidson M. Risk of cardiovascular disease and sudden death in schizophrenia. J Clin Psychiatry 63 Suppl. 9 (2002) 5-11
17. Expert Consensus Meeting. 'Schizophrenia and Diabetes 2003' Expert Consensus Meeting, Dublin, 3-4 October 2003: consensus summary. Br J Psychiatry Suppl. 2004;47:S112-4.
18. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP). JAMA 2001 16;285(19):2486-97.
19. Fleiss J. Statistical Methods for Rates and Proportions. 2nd ed. (1981)
20. Green A.I. Schizophrenia and comorbid substance use disorder: effects of antipsychotics. J Clin Psychiatry 66 Suppl. 6 (2005) 21-26
21. Grundy S.M. A constellation of complications: the metabolic syndrome. Clin Cornerstone 7 2-3 (2005) 36-45
22. Gual A., Contel M., Segura L., Ribas A., and Colom J. The ISCA (Systematic Interview of Alcohol Consumption), a new instrument to detect risky drinking. Med Clin (Barc) 117 18 (2001) 685-689
23. Han T.S., van Leer E.M., Seidell J.C., and Lean M.E. Waist circumference action levels in the identification of cardiovascular risk factors: prevalence study in a random sample. BMJ 311 7017 (1995) 1401-1405
24. Henderson D.C. Schizophrenia and comorbid metabolic disorders. J Clin Psychiatry 66 Suppl. 6 (2005) 11-20
25. Hennekens C.H., Hennekens A.R., Hollar D., and Casey D.E. Schizophrenia and increased risks of cardiovascular disease 1. Am Heart J 150 6 (2005) 1115-1121
26. Instituto Nacional de Estadística. Padrón municipal de habitantes. Anuario estadístico de España 2004[(2.1 Población por comunidades autónomas 2003)]. 2006.
27. Kato M.M., Currier M.B., Villaverde O., and Gonzalez-Blanco M. The relation between body fat distribution and cardiovascular risk factors in patients with schizophrenia: a cross-sectional pilot study. Prim Care Companion J Clin Psychiatry 7 3 (2005) 115-118
28. Lehman A.F., Lieberman J.A., Dixon L.B., McGlashan T.H., Miller A.L., Perkins D.O., et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 161 2 Suppl. (2004) 1-56
29. Marder S.R., Essock S.M., Miller A.L., Buchanan R.W., Casey D.E., Davis J.M., et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 161 8 (2004) 1334-1349
30. McEvoy J.P., Meyer J.M., Goff D.C., Nasrallah H.A., Davis S.M., Sullivan L., et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 80 1 (2005) 19-32
31. Muck-Jorgensen P., Mors O., Mortensen P.B., and Ewald H. The schizophrenic patient in the somatic hospital. Acta Psychiatr Scand Suppl 407 (2000) 96-99
32. Osby U., Correia N., Brandt L., Ekbom A., and Sparen P. Mortality and causes of death in schizophrenia in Stockholm county. Sweden. Schizophr Res 45 1-2 (2000) 21-28
33. Paton C., Esop R., Young C., and Taylor D. Obesity, dyslipidaemias and smoking in an inpatient population treated with antipsychotic drugs. Acta Psychiatr Scand 110 4 (2004) 299-305
34. Rejas J., Bobes J., Arango C., Aranda P., Carmena R., and Garcia-Garcia M. Concordance of standard and modified NCEP ATP III criteria for identification of metabolic syndrome in outpatients with schizophrenia treated with antipsychotics: a corollary from the CLAMORS study. Schizophr Res 99 1-3 (2008) 23-28
35. Ryan M.C., and Thakore J.H. Physical consequences of schizophrenia and its treatment: the metabolic syndrome. Life Sci 71 3 (2002) 239-257
36. Saiz R.J., Bobes G.J., Vallejo R.J., Giner U.J., and Garcia-Portilla Gonzalez M.P. Consensus on physical health of patients with schizophrenia from the Spanish Societies of Psychiatry and Biological Psychiatry. Actas Esp Psiquiatr 36 5 (2008) 251-264
37. Sokolow M., and Lyon T. The ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads. Am Heart J 37 (1949) 161-186
38. Taylor D.M., and Duncan-McConnell D. Refractory schizophrenia and atypical antipsychotics. J Psychopharmacol 14 4 (2000) 409-418
39. The American Diabetes Association. http://wwwdiabetesorg/homejsp 2009 [cited 6 Oct 2005];Available from: URL: http://www.diabetes.org/home.jsp.
40. Weiden P.J., Mackell J.A., and McDonnell D.D. Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res 66 1 (2004) 51-57
41. WHO/MSD/MSB/00.3. Guide to drug abuse epidemiology. 2006. p. 403-6.
42. Wirshing D.A. Schizophrenia and obesity: impact of antipsychotic medications. J Clin Psychiatry 65 Suppl. 18 (2004) 13-26